Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

405
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
405
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

306
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
306
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

445
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
445
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

301
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
301

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Mechanical properties of thermoformed and direct-printed aligner materials after immersion in 37 °C water: a 14-day in vitro study.

Scientific reports·2026
Same author

Are diffusion models ready for materials discovery in unexplored chemical space?

Patterns (New York, N.Y.)·2026
Same author

Prediction of low birth weight using machine learning-based analysis of environmental and maternal risk factors: insights from the Korean CHildren's ENvironmental health study (Ko-CHENS).

Environmental research·2026
Same author

Pilot study of a community-based PM<sub>2.5</sub> educational intervention: impacts on behavior, exposure, and pulmonary function.

BMC public health·2026
Same author

Core-Shell Redox-Nanoparticles Integrate High Ammonium Selectivity with Long-Term Stability.

ACS nano·2026
Same author

The EphA3 Antibody Enhances CD47 Antibody-Mediated Phagocytosis by Repolarizing M2-Like Tumor-Associated Macrophages in a Preclinical Model of Recurrent Head and Neck Cancer.

OncoTargets and therapy·2026

Related Experiment Video

Updated: Jul 6, 2025

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

1.7K

IL-1β and iNOS can drive the asthmatic comorbidities and decrease of lung function in perennial allergic rhinitis

Myung Woul Han1, Song Hee Kim2, Inbo Oh3

  • 1Department of Otolaryngology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea. brightmoon@uuh.ulsan.kr.

Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|January 3, 2024
PubMed
Summary

Interleukin-1β (IL-1β) and inducible nitric oxide synthase (iNOS) indicate asthma comorbidity in children with perennial allergic rhinitis (PAR). Higher levels correlate with reduced lung function, suggesting early intervention targets.

Keywords:
Allergic rhinitisAsthmaComorbidityE-cadherinEpithelial-mesenchymal transitionIL-1βVimentiniNOS

More Related Videos

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

10.4K
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

30.3K

Related Experiment Videos

Last Updated: Jul 6, 2025

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

1.7K
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

10.4K
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

30.3K

Area of Science:

  • Immunology
  • Pediatric Allergy
  • Respiratory Medicine

Background:

  • Allergic rhinitis (AR) and asthma frequently coexist, necessitating early detection of this comorbidity.
  • Identifying early indicators can facilitate timely treatment and prevent asthma progression in AR patients.
  • Perennial allergic rhinitis (PAR) affects children, with a subset developing asthma.

Purpose of the Study:

  • To investigate the role of interleukin-1β (IL-1β) and inducible nitric oxide synthase (iNOS) in PAR-asthma comorbidity.
  • To assess the association of IL-1β and iNOS with lung function in children with PAR.
  • To explore biomarkers including IL-1β, iNOS, and epithelial-mesenchymal transition (EMT) markers in Korean children.

Main Methods:

  • Analyzed a cohort of 240 Korean children (6-10 years) with PAR (PAR alone vs. PAR and asthma).
  • Measured serum levels of IL-1β, CCL-24, E-cadherin, and vimentin using ELISA.
  • Quantified epithelial iNOS using a NOS kit and examined blood eosinophils and IgE.

Main Results:

  • Elevated serum IL-1β, iNOS, and vimentin levels were significant indicators of PAR-asthma comorbidity.
  • Higher concentrations of IL-1β, iNOS, and vimentin correlated with reduced lung function in PAR children.
  • IL-1β expression related to E-cadherin, vimentin, and CCL-24; no correlation found between IL-1β and iNOS.

Conclusions:

  • IL-1β and iNOS serve as potential biomarkers for PAR-asthma progression and decreased lung function.
  • These biomarkers suggest possible targets for early intervention strategies in pediatric respiratory conditions.
  • Prompt identification of these markers may aid in preventing asthma development in children with PAR.